Nohla Therapeutics raises $11M to advance dilanubicel after 86% five-year survival in early study

Nohla Therapeutics raised an additional $11 million to advance dilanubicel, its umbilical-cord–derived stem cell treatment for leukemia, which showed 86% five-year survival in an early study with no severe graft-versus-host disease. The therapy is in Phase II trials and aims to offer an off-the-shelf alternative to matched bone marrow transplants while reducing early infection risks.

No comments yet.